ŠĻą”±į>ž’ ÖŲž’’’ŌÕ’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ģ„Į#` šæöEbjbj”” .”ĆĆ–;n’’’’’’¤@@@@@@@²¤‚‚‚8V‚¤ś‚”V!jģjšƒšƒ°ƒ°ƒ°ƒ°ƒ°ƒ°ƒŃėÓėÓėÓėÓėÓėÓė$Ōķh<šŒ÷ė-@°ƒ°ƒ°ƒ°ƒ°ƒ÷ė@@°ƒ°ƒ$ģ–Œ–Œ–Œ°ƒ4@°ƒ@°ƒŃė–Œ°ƒŃė–Œ–ŒžÆߘ@@3ē°ƒŽƒ  ŃIŹjČ‚䉚GāHŃė:ģ0jģā¤ČšŌ‹øČš3ē3ē²Čš@åčģ°ƒ°ƒ–Œ°ƒ°ƒ°ƒ°ƒ°ƒ÷ė÷ėŒŒ °ƒ°ƒ°ƒjģ°ƒ°ƒ°ƒ°ƒV!V!V!9ZZÄ'V!V!V!ZZTŌ(†®@@@@@@’’’’  Nutrition MCQ June 2007 The following Multiple Choice Questions have ONE single best answer. Please circle the best answer. 1. Which of the following nutritional factors has been shown to BEST predict long term morbidity and/or mortality? A. BMI >30 or <18 B. >10% weight gain in the previous 6 months C. Percent body fat >22% (men) or >35% (women) D. Total fat intake >30% of consumed calories E. Total protein intake <40% of consumed calories 2. There is much evidence in favor of diets high in monounsaturated fat. The potential drawback of this diet compared with diets high in complex carbohydrates is that monounsaturated fat may result in: A. Higher energy intake B. Higher cholesterol levels C Higher triglyceride levels D. Lower HDL levels E. Higher insulin resistance 3. Which one of the following options represents historical features of the Subjective Global Assessment? A. Weight loss and gastrointestinal symptoms B Malignancy and nausea C. Family history of IBD and personal history of weight loss D. Family history of Celiac Disease E. Functional impairment and recent hospitalization 4. Which of the following is an ABSOLUTE contraindication to parenteral nutrition? A. Diarrhea B. Liver cirrhosis C. Malignancy D. Active Infection E. Osteoporosis 5. Which one of the following options represents potential complications of enteral nutrition? A. Osteoporosis and refeeding syndrome B. Diarrhea and cholestasis C. Esophagitis and pancreatitis D. Aspiration and refeeding syndrome E. Aspiration and Constipation 6. Enteral nutrition is preferred over parenteral nutrition for all of the following reasons EXCEPT: A. Lower risk of electrolyte abnormalities B. Lower risk of refeeding C. Lower risk of liver disease D. Improved Glycemic control E. Stimulate gut barrier function Questions 7 and 8 refer to the following stem: You are asked to see a 26 year old man with Crohn’s disease. He has been admitted to hospital 3 days ago with a small bowel obstruction secondary to fibrostenotic disease of the terminal ileum. Prior to 3 days ago, his oral intake was normal despite ongoing abdominal pain and diarrhea related to his Crohn’s disease. He has lost 2kg since hospitalization, but his weight was stable prior to that. He is scheduled for surgery tomorrow for terminal ileal resection. His surgeon asks for your advice regarding nutrition support. 7. Would you start TPN today, expecting post-operative benefit? A. No; studies of benefit of pre-operative nutrition have shown benefit only in patients who receive TPN for > 7 days prior to surgery. B. Yes; he is at risk for poor wound healing and infection based on his recent weight loss C. Yes; studies of benefit of pre-operative nutrition have shown benefit in patients who receive TPN in the immediate peri-operative setting D. Yes; studies of benefit of pre-operative nutrition have shown benefit in preventing recurrence of Crohn’s disease at the anastomotic site E. No; he is young with no major comorbidities therefore at low risk of nutritional complications. 8. Would you recommend delaying surgery for TPN to improve outcome? A. Yes; he is at risk for poor wound healing and infection based on his underlying disease and recent weight loss B. Yes; he may have reduced oral intake post-operatively and lose more weight C. No; he is young with no major comorbidity therefore at low risk of nutritional complications D. No, however he should maximize enteral nutrition for 24 hours pre-operatively E. No; patients who are severely malnourished are most likely to benefit. 9. Which of the following statements regarding enteral nutrition formulas is TRUE? A. Polymeric formulas are those that contain all macronutrients in whole (ie non- hydrolyzed) form; semi-elemental formulas do not contain all three macronutrients B. For acute pancreatitis within 48 hours of hospital admission, jejunal delivery of semi-elemental formulas is the preferred form of nutrition support C. Enteral formulas are formulated to provide adequate micronutrients if caloric requirements are being met D. Specialty formulas for liver and pulmonary disease are superior to regular polymeric formulas in patients with cirrhosis and COPD, respectively E. Semi-elemental formulas are more cost-effective than polymeric formulas 10. Which of the following is an acceptable method for determining caloric needs for nutrition support? A. Caloric needs per kilogram of body weight (ie 25-30 kcal/kg body weight) B. Underwater weighing C. Cockcroft-Gault equation with activity modifier D. Anthropometry and Body impedance analysis E. Maintaining and interpreting a 7-day detailed food record 11. Which of the following is NOT a clinical consequence of refeeding syndrome? A. Hypophosphatemia B. Hypomagnesemia C. Hypervolemia D. Hyperphosphatemia E. Hyperglycemia 12. Which one of the following micronutrients is routinely added to TPN? A. Vitamin D B. Iron C. vitamin E D. Vitamin K E. Manganese 13. A 50 year old man had a massive small bowel resection secondary to a volvulus 1 year ago, leaving him with 75cm of small bowel. If he did not receive adequate nutrition support, how long would it take to develop biochemical or clinical evidence of essential fatty acid deficiency? A.4 days B. 4 weeks C. 4 months D. 1 year E. 4 years 14. Which one of the following medications can be added to TPN in the appropriate clinical circumstance? A. H2 Receptor Antagonists B. Proton pump inhibitors C. Fluroquinolones D. Narcotics E. Cephalosporins 15. Which one of the following statements is TRUE regarding central venous catheter infections in patients receiving long term home total parenteral nutrition: The most common organism causing catheter infection is Staphylococcus Aureus. Double lumen catheters reduce the risk of catheter infection compared with single lumen catheters. Femoral catheters reduce the risk of catheter infection compared with subclavian catheters In an uncomplicated catheter infection the accepted standard of care is to start antibiotic therapy without removing the catheter Tunneled catheters may reduce the risk of catheter infection compared with implanted catheters 16. In which of the following clinical situations should >1.0g protein per kg body weight be provided in nutrition support? A. Patients with renal failure on hemodialysis B. Hospitalized patients C. Obese patients D. Cirrhosis with hepatic encephalopathy E. Ventilated patients 17. Which one of the following gut hormones is responsible for promoting appetite? A. Leptin B. Grehlin C. Peptide YY D. CCK E. Insulin 18. Which one of the following hormones plays an important role in inhibiting appetite? A. Grehlin B. Resistin C. TNF ± D. Peptide YY E. Neurotensin 19. Which of the following statements is TRUE regarding weight reducing agents and mechanism of weight loss? A. Orlsitat exerts its action by selectively blocking cannabinoid-1 receptors B. Sibutramine exerts its action by inhibiting pancreatic lipase C. Sibutramine exerts its action by selectively blocking cannabinoid-2 receptors D. Rimonabant exerts its action by selectively blocking cannabinoid-1 receptors E. Rimonabant exerts its action by selectively blocking pancreatic lipase 20. Which of the following statements regarding the side effects of weight reducing agents is TRUE: A. Orlistat can predispose to cardiac arrythmias B. Rimonabant can predispose to cardiac arrythmias C. Sibutramine can predispose toward abdominal diarrhea and steatorrhea D. Sibutramine can predispose toward cardiac arrythmias E. Rimonabant can predispose toward diarrhea and steatorrhea 21. Which of the following is NOT an adipocytokine: A. Leptin B. Resistin C. Adiponectin D. Grehlin E. IL-6 22. Which of the following is an acceptable indication for pharmacotherapy to induce weight loss in overweight/obese adults? A. BMI > 27 and unsuccessful attempt at lifestyle modification for preceding 6 months B. BMI > 30 and unsuccessful lifestyle modification for preceding 6 months C. Waist circumference > 102 cm in males D. Waist circumference > 88cm in females E. Waist circumference > 102 cm in males and > 88cm in females and an unsuccessful attempt to lose weight through lifestyle modification for the preceding 6 months 23. Which of the following statements is TRUE regarding probiotics? A. Probiotics are organisms that contribute toward intestinal microbial balance B. Probiotics are non-digestible food products that selectively stimulates the growth of one or a limited number of bacteria in the colon to confer health benefit for the host C. There is good evidence to suggest that probiotics have a beneficial role in preventing post-operative recurrence of Crohn’s Disease D. VSL#3 probiotic consists of strains of lactobacillus, bifidobacterium and Saccharomyces boulardi E. Milk is an example of a food source containing probiotics. 24. Which of the following in an example of a prebiotic? A. Yogurt B. Inulin C. Creatinine D. Fish Oil E. Vitamin C 25. All of the following are manifestations of zinc deficiency EXCEPT: A. diarrhea B. dysgeusia C. alopecia D. rash E. parasthesias Questions 26 and 27 refer to the following stem: 26. You are asked to assess a 50 y.o male with short bowel syndrome. This patient had a small bowel resection secondary to mesenteric ischemia 2 months ago, leaving him with 150 cm of residual small bowel and an end jejunostomy. He is now dependant on TPN 5 days per week. He is having 3 L of stool output per day. There is no evidence of enteric infection. Which of the following pharmacological options is the most reasonable next therapeutic option? A. Flagyl 500mg po bid B. cipro 500mg po bid C. cipro 500mg IV q12h D. codeine 30mg po qid E. Flagyl 500mg IV q12h 27. The patient in Question 2 above develops gradual onset of shortness of breath, 3-pillow orthopnea, and paroxysmal nocturnal dyspnea with mild ankle edema over a period of eight months. These symptoms may be a result of which of the following: A. Zinc deficiency B. Chromium deficency C. Selenium deficiency D. Manganese deficiency E. Vitamin E deficiency 28. When does MAXIMAL small bowel adaptation occur post small bowel resection? A. 2 months B. 6 months C. 8 months D. 18 months E. 4 years 29. Which of the following foods does not contain gluten and is acceptable for patients with celiac disease to consume? A. Bran B. Spelt C. Rice D. Graham E. Beer 30. A 85 y.o male patient has decreased his intake of animal protein and increased his intake of whole grain toast, cereal and salads over the past 12 months. Which of the following micronutrient deficiencies is he at risk for? A. Chromium B. Selenium C. Folate D. Zinc E. Magnesium 31. A 35 year old morbidly obese female underwent vertical band gastroplasty (VBG) 6 months ago. She has lost 50 lbs of weight over 6 months. She is now complaining of 6-8 loose watery bowel movements per day ongoing for the past 2 months. Prior to 2 months ago she was having 1 formed bowel movement per day for years. Which of the following statements regarding this scenario is TRUE? A. The diarrhea is likely related to malabsorption from the VBG and is the primary mechanism of weight loss B. The diarrhea is likely a consequence of small bowel bacterial overgrowth which may be a consequence of the VBG C. She is immunosuppressed secondary to the weight loss and the diarrhea may be related to C. Difficle colits D. The diarrhea is not related to the VBG and requires a full work-up E. She has been consuming mainly liquids due to the small pouch capacity, consequently this limits formation of stools. 32. Which of the following statements regarding protein intake in patients with chronic liver disease is TRUE: Protein restriction should NOT be considered routinely in patients with chronic liver disease including in those with hepatic encephalopathy Patients with chronic liver disease and encephalopathy should receive protein in quantities between 0.25-0.5g/kg/d Animal sources of protein should be consumed more frequently in patients with chronic liver disease Patients with chronic liver disease should receive protein in quantities between 2-2.5g/kg/day Patients with chronic liver disease should receive protein in quantities between 0.5-0.75g/kg/d 33. Which of the following statements regarding macronutrient energy value is TRUE: A. Carbohydrates provide 9kcal/gram consumed B. Protein provides 2 kcal/gram consumed C. Fat provides 7kcal/gram consumed D. Protein provides 4 kcal/gram consumed E. Fat provides 12kcal/gram consumed 34. Which of the following statements regarding Fiber is TRUE? A. Insoluble fiber has been shown to reduce total cholesterol B. Insoluble fiber has been shown to improve blood sugar control in diabetics C. Soluble fiber enhances gastric emptying D. Soluble fiber has been shown to lower the risk of pancreatic cancer E. Soluble fiber has been shown to reduce total cholesterol 35. Which of the following values represent the recommended daily intake of fiber per day? A. 35-40g B. 25-30g C. 15-20g D. 10-15g E. 5-10g 36. In studies that have compared enteral nutrition to corticosteroids in adult patients with active Crohn’s Disease, what percentage of patients treated with enteral nutrition alone enter into clinical remission? 20% 40% 60% 80% >80% 37. Which of the following patients with short bowel syndrome is likely to require long term Home Total Parenteral Nutrition? Small bowel length of 200cm with end jejunostomy Small bowel length 200cm with jejunocolic anastomosis Small bowel length 100cm with jejunocolic anastomosis Small bowel length 75 cm with end jejunostomy Small bowel length 60 cm with jejunocolic anastomosis 38. A product lists the following nutrition information: Serving size 9oz Servings per package 1 Calories 240 Protein 19g Carbohydrate 19g Fat 10g What is the percentage of calories provided by fat in this product? 30% 34% 38% 42% E. 50% 39. Which of the following components of energy expenditure generally accounts for the largest proportion of the 24h energy expenditure total? Thermic Effect of Food Resting Energy Expenditure Activity related energy expenditure Energy of fidgeting Energy of Catabolism 40. A 50 year old male is admitted to the ICU with respiratory distress secondary to pneumonia. He is now ventilator dependant. He is started on polymeric enteral feeds at 20cc/hour. After 2 days of feeds, his nurse notices that the gastric residual is 100cc and she is concerned about the risk of aspiration. The best recommendation in this situation is: Stop enteral feeds and start parenteral nutrition Reduce the rate of the enteral feed to 10cc/hour Change the polymeric formula to semi-elemental formula Start Domperidone 10mg qid Make no change to the current rate or type of feed as the risk of aspiration is low     Nutrition Curriculum MCQ Pre-Test Name: __________________________________________  PAGE 1 RUVˆŠ‹ŒŽĢŃŚŪ       E F I u v y ¤ „ × Ų Ü Ż ó öźöåąÜŌąÜöĶĽø°«°ø°¦”–’‹„’‹’‹„’‹„’‹yuqihąW7h(¤5hĘKŪh(¤hBÜh@güB*ph’ hP1’h@gü hP1’hP1’hP1’hBÜhtB®B*ph’ hī+Œ5 hõ^U5 hūƒ5hP1’h@gü5 hL¹5 hč*;hŁ[Óhč*;5CJ,aJ, hžK_hžK_hžK_hLĄ5hLĄ hLĄ5 hSds5h[ ]hLĄ5CJ(aJ(hLĄ5CJ(aJ(' !"#$%‰‹Œ   E u ¤ × Ų śśśśśśśśśśśśśśśśųųėųęęęęęųgdP1’ „Š„0ż^„Š`„0żgd¤ČgdLĄ‡EõEżżó ’ # A N ¢ £ ¤ „ - . 0 1 5 ; ? P c m  › œ  „ … ˆ £ ­ ¾ × Ų Ł ę ē ė ū ’ śņķņķņčŪč׊×ĢČĄ»Ą»³Ą³¦™Č•‘Œ‡Œuhd•d•d•hŌyøhõ^UhYW5B*ph’hõ^U5B*ph’hī+ŒhYW5 h“z¾5 h;5hź'hYWhL¹h>¬5B*ph’hL¹hõ^U5B*ph’hL¹hz)˜5 hz)˜5hL¹h>¬5h>¬hč*; hąW7h(¤h(¤hż h(¤5B*ph’ h(¤5 hĘKŪ5hąW7h(¤5 h¤Č5&Ų ¤ „ ¾ Ü ś  . / 0 1  ž Ģ ē & M ƒ „ … Ł Ś ē ņķķķķķķėėėŽėėėėėėėėŃČæ„h^„hgdŌyø„8^„8gdŌyø „h„˜ž^„h`„˜žgd“z¾ „Š„0ż^„Š`„0żgdz)˜gd(¤ „Š„0ż^„Š`„0żgd¤Čē ū 1 2 4 ƒ › œ Ä į (HIÆ°Üų6YZ‰ööööōļźįļļļļļļļÜ××××××ŅŅgd»'ggdYWgd_u„h^„hgd„s„gdoFgdź'„h^„hgdŌyø   $ 0 2 3 4 7 = A R d € ‚ ƒ ˆ ™ š › IL­®ÆYZ‰Š‹_`a”¤üųōšģōčäąŲÓŲÓŲÓĪąĘÓ¹µ±©””±ˆ„€xsfa hZž5hõ^Uh»'g5B*ph’ hõ^U5hī+Œh»'g5hZžhź'hZžhZž5h»'gh_uh |Ŗ5B*ph’h_uhģŚ5h_uh  5h  hgAh„s„h„s„5B*ph’h„s„h„s„5 hgA5 h„s„5hč*;hgA5h„s„hī+ŒhL¹hsYhŌyøhYWh“z¾htB®#‰‹ab ”āćmoĢĶ\]ģķRSTU›œ`aĆÄśśśśśśśśśśśśśśśśśśśśśśśśśśśśśgd»'g¤ąįāĶĻ\RSTUY~š›abefhijŠ”³ø¹ŗ»æ QRabdz łū÷ļāŽŚŽŚŽÖŃĢļƫ¤« «œ”””Š€so o o ok g oh†M½hŻ:ĶhQEęhõ^UhtB®5B*ph’h@gü5B*ph’ hõ^U5 hQEę5hī+Œhߎ5hź'hߎ hŽlhŽlhŽlhõ^UhŽl5B*ph’hŽlhߎ5hŽlh»'g5 hŽl5 hLĄ5hČ.RhfYhM”hõ^Uh»'g5B*ph’hfYhM”5hfYh»'g5(bcefŗ»ałgüHI²³Lzø¹ŗ»½¾æśśśśųųóźóóóųŻŻŲŲŲŲŲųųųųųųgdSV „Š„0ż^„Š`„0żgdāI4„Š^„Šgd†M½gdŻ:Ķgd»'gūżKLfgik¶·üHIKMio{°±²³·L~Žš·ø¹»¼æĆ&+vx~‚…¤„üųüųōšüųüųšųģčćŪćŪÖŃÄĄčĄčĄčĄ¼ø¼Ąčø“ø°Ø֛°—°“‹†‹†‹ hĻn5hī+Œh¤Rœ5h¤RœhßdShõ^UhĻn5B*ph’hsD©hĻn5hĻnhČ.RhŅKŃh7UhSVhõ^Uhnb5B*ph’ hź'5 hõ^U5hī+Œh¾^5 hāI45h¾^hŽlhQEęhߎhź'hŻ:Ķ1æ&9J`rst¾æĶÖäņ !+7DO[\żżżżżżżżżżżųųųųųųżėżżżżżżż „Š„0ż^„Š`„0żgdßdSgdĻn„®¼½¾æĄĆĶŃÖŚćäčņó’¶·¹ĮĘž "$+/07;CGNSöīéäŁŅĒ¼Ē¼Ē“¼Ē¼Ē°¬Ø¤ ˜“ī“ī‡ézun¤¤j¤¤hČ.R hsD©hsD© hsD©5hõ^Uh¤Rœ5B*ph’hī+ŒhcĀ5hßdS hßdS5hßdShßdS5hüžhsD©h¤RœhĻnhü'}hü'}mHsHhūƒh¤RœmHsHhūƒhĻnmHsH htB®hĻnhtB®h-PB*ph’ h¤Rœ5 hõ^U5hī+Œh¤Rœ5hī+Œh¤Rœ5>*)SZ[\^`fj¤ĆÄÅĘĒĖāēž $234AKOįā”›Śä < q ½ ¾ Ń Ņ Ó Ō Ö üųüōščćčć莣ĢČÄČųČÄųČĄųČšųš¼“¬“Ÿ›¼›¼›—›“›“Œ„€xh#hņe5hī+ŒhėTrB*ph’ hnbhģ³hģ³hnbhėTrhnbhėTr5B*ph’hnbhāI45hnbhėTr5h‹@5h>mHh¢7Īhy?rhõ^Uh-P5B*ph’ hcĀ5 hõ^U5 hy?r5hī+ŒhcĀ5hüžhņehcĀhßdS.\ĘĒćž 3456789:;<=>?@Aāć1”ļņņķķķķķėėėėėėėėėėėėėėėėććć & F!gdėTrgdy?r „Š„0ż^„Š`„0żgd-Pļq ¾ Ņ Ó Ō R!S!‚!›!­!Ö!ķ!ī!ļ!H"J"T"`"o"w"ƒ"„"‹"÷ļęääääŪŪŪŪŪÖÖŃÖČÖÖÖÖÖÖ„Š`„ŠgdāI4gd#gddeö„Š^„Šgd„8^„8gdģ³ & F!gdģ³ & F!gdėTrÖ × Ų '!(!P!Q!R!S!V!c!!‚!…!›!¬!­!°!Ö!Ł!ģ!ķ!ļ!š!ń!ņ!ó!ō!ś!ž!9"="F"G"H"I"J"K"T"V"`"b"n"o"q"w"y"÷óėęėįÜĻĖóĒóĖóĖóĖóĖĆóæ·Æ§£Ÿ—’—’—į…}ŸŸyŸŸuhŅKŃh#hāI4hĄphõ^Uhdeö5B*ph’ hāI45hī+ŒhŃ5hŃhVM1h#hVM15h#hņe5h#hŃ5hdeöhēchČ.Rhhõ^Uhēc5B*ph’ hüž5 hõ^U5 hVM15hī+Œh(t5h(th#h(t5.y"ƒ"Š"Œ""‘"’"“"”"•"–"œ" "ą"į"ź"ė"ģ"ķ"ļ"š"ū"ü"# #$$$$ $"$$$B$D$H$J$L$P$d$ %"%üųōųģēāŪų×ģŅģēģĶĄ¹²§œ§œ§œųœ§”œ§üŒ„|tlgĶ hĄp5hĄphĄp5hėj#hĄp5hėj#hņe5hėj#hVM15h1=Ģh”BNh#mHsHhūƒhŃmHsHhūƒhĄpmHsH htB®hVM1 htB®hŃhtB®hŃ5B*ph’ hõ^U5 hāI45hVM1 hī+ŒhŃ hņe5 hVM15hī+ŒhŃ5hČ.RhŃhĄp(‹""Ž"ģ"ī"ś"#$"$B$D$F$H$$%&%(%Ę%%&w&Č&''''{'|'®'ā'+(d(śśśśśśśśśśśśśśśśśśśśśśśśśśśśśgddeö"%$%&%(%Ę%ä%&½&''''''F'J'y'z'{'|'€'¦'©'­'®'Ś'Ż'\(](”(¢(£(¤(„(¦(©(Č(×(Ų(Ł()óļčļäļąļąļÕŃĶÅĄÅ»®©Ķ„”„Ķ„”„”„šĶ“Ž‰|»okh6`hõ^Uh>5B*ph’ h(0w5hVM1h6`5 hņe5 hŚG5 h5"īhtB® h5"īh“eŸhĪ$>h“eŸ h5"ī5hõ^Uh‰N25B*ph’ hõ^U5 hāI45h5"īh5"ī5h5"īhņehų/Ōh‹<B*ph’hz*Åhėj# hĄphĄphĄphõ^UhĄp5B*ph’(d(¢(£(¤(Ł(Ś(å(ņ()))))))))›)œ)ō)õ)A*B*l*m*—*˜*?+@+A+śśśśśśśśśśśśśśśśśśśśśśśśśśśśśgddeö) )))))))))!)™)š)›)œ))ž)ģ)ķ)õ)ö)÷)B*C*D*m*n*o*–*—*>+?+@+A+D+E+F+_+üųńéŽÓĻĖĒĄø³¦ĄĖ¢ĄĖĄĖ¢ĄĖ¢ĄĖ¢Ąžš“ˆ}xsnfhP½h$Ļ5 hņe5 hŚG5 h>Ļ5hų/Ōh’/½B*ph’hų/ŌhS€B*ph’ hŃhŅKŃhŅKŃh@×hŃhõ^Uh@×5B*ph’ hõ^U5hŃh@×5 hŃh@×hņehVM1h1=Ģhų/Ōh@×B*ph’hų/Ōh”.|B*ph’h6K¢B*ph’ h6`h6`h6`hČ.R%A+B+C+D+Š+‹+Ü+™,(-”-Ó-Ō-Õ-Ö-×-...(.7.D.R.S.T.U.V..ž.«.¹.śśśśśśśśśśśśśśśśśśśśśśśśśśśśśgddeö_+|+}+†+‡+ˆ+‰+Š++ž+ą+š+ , ,,,2,l,˜,,'-(-,-“-”-˜-Ņ-Ó-Ö-×-Ų-Ł-.....Q.R.÷ļåŪļÖÉÅĮÅĮŽÅĮÅĮÅĮÅĮ¹Į¹µ®£˜“Ž†|†Öokd hohohohõ^Uh’/½5B*ph’hP½ho56hP½ho5 hņe5 hVM15h$D[h’/½B*ph’h$Ļh}dķB*ph’ h$Ļh$D[h+O^h$D[hō ©hdh$Ļhõ^Uh}dķ5B*ph’ hõ^U5hP½hd56hP½h$Ļ56hP½h$Ļ5hP½hd5%R.S.T.U.V.X.Z.•.œ..ž.Ÿ. .«.­.¹.».Ę.Ē.Č.Ļ.Ń.ą.į.///////W/ōéįŌŠÉĮ¼·°©ž“‹“‹“€|É|Étlglc\Š\ThÕ™h®px5 hÕ™hģ 4h’^ h>Ļ5h’^h’^5hģ 4B*ph’hyo„hūƒhyo„mHsHhyo„mHsHhyo„h{4wmHsHhyo„hyo„mHsH hVM1hyo„ hyo„hpVd h{4w5 hpVd5hyo„h{4w5 hyo„h{4whņehVM1h{4w5B*ph’hVM1hķÕ5hūƒhķÕB*ph’hoh’/½B*ph’¹.Ę.Ļ.ą.į.///Ś0Ū0ó0 1"1:1S1T1U1M2N2b2y2‘2Ŗ2Ć2Ä2Å233#3śśśśśśśśśśśśśśśśõõõõõõõśśśśśgd’^gddeöW/X//°/±/Į/į/÷/$0‡0 0Ų0Ł0Ś0Ū0Ü0Ż0ó0õ0 1 1"1$1:1;1<1R1S1T1U1W1Ė1Õ1é1 2K2L2M2Å2Ę2śņśņśņśņźņźåŲŃŹĀ·Ā·Ā·Ā·Ā°©„ž“Ž†Ž†Ž†Žyumh’^hŚG5h’^hõ^Uh’^5B*ph’hP½h’^5 h’^5hVM1h{[›B*ph’ hVM1h>Ļh®px hVM1h®px hVM1hÕ™hÕ™h®pxmHsHhÕ™mHsH htB®hÕ™ htB®h®pxhtB®hģ 45B*ph’ hõ^U5hÕ™h®px5hÕ™h{[›5 hāI45'Ę2Ē2Č2É2Ū233333"3#3/30323=3?3K3M3V3W3X3Y3Z3[3\3^3Ó3Ō3Õ3Ö3×3Ų3÷ļčćŪŃÄčĄč¼ø±øčøčøč¼ø±¦Ÿš•ˆ{qd\hņ7TmHsHhų/Ōh±&®5B*ph’hõ^U5B*ph’hõ^Uh±&®5B*ph’ hõ^U5hmhĘh±&®5 hņe5 hLĄ5 hP½hP½hų/Ōh{[›B*ph’ hP½h>Ļh>Ļh{[›hP½hõ^Uh{4w5B*ph’h’^5B*ph’hP½h{[›5 h²*k5 hP½h{[›h’^h{[›5h’^h’^5 #303=3K3W3Y3Z3[3\3Õ3×3ß3č3š3ś3444é4ź4÷4555&5'5(5¬6­6śśśśśśśśśśśśśśśśśśśśśśśśõõõõgdß<4gddeöŲ3ß3ą3č3é3š3ń3ł3ś3ż344444ē4č4é4%5&5(5*5+5u5{5‰5¶5Ŗ6«6¬6±6¼6Ü6 7!7[8Š8õķõķõķõåķŻŅĆ¾¹±¬Ÿ›”¹ˆ€{€{€¬njfjjbhžzyhÄ_”hm\čhõ^Uhl;5B*ph’ hm\č5h„LGh„LG5h„LGhVM15h„LG hmhĘhmhĘhmhĘhõ^UhmhĘ5B*ph’ hõ^U5h„LGhmhĘ5 hņe5 hźaj5hų/Ōhż}B*mHph’sHhmhĘhņ7TmHsHhźajmHsHh±&®mHsHhņ7TmHsHhmhĘh±&®mHsH$­6!7›78W8Ń8Ņ8Ó8Ō8Õ8Ö8×8Ų8Ł8I9J9×9J:®: ;m;n;o;Ä;Å;śśśśśśõõõõõõõõģäÜÜÜÜŚõõÕgdŽZ˜ & Fgddeö & Fgd%‡„Š^„Šgd%‡gdņegdß<4Š8Ń8Ņ8Ų8Ł8Ż8G9H9I9J9×9I:J:­:®: ; ;l;m;n;o;s;Ā;Ć;Ä;Å;Č;ņ;õ;<<?<B<h<k<Ž<’<Ģ<Ķ<Ī<Ļ<Ņ< ==^=…=§=Ģ=Ķ=Š=üųóīéįÜŌŠÉÅĮÉŗ¶Š¶Æ«¦éžÜžš–š–š–š–š–šéŽÜŽŠ†Š†Š‚Š~Š†hĮlŻhQOAh‡G¶hƒžh(.ēhƒž5hY}ąhŽZ˜hŽZ˜hŽZ˜5 hźaj5hų/Ō h%‡hed¼hed¼ h%‡hß<4h“Fhäø h%‡h%‡h%‡hin$hz 5 hõ^U5hin$h%‡5 hņe5 hLĄ5 h1=Ģ5hžzyhz 1Å;ņ;<?<h<<Ž<Ī<Ļ< =[=†=Ķ= > > > >h>i>s>}>öķķķķčćŽÕĢĢĢĢĆĆćć¾µ¬„Š`„Šgdųa¬„Š^„Šgdųa¬gdÜ„8^„8gdƒž„Š`„Šgd‡G¶„Š^„Šgd‡G¶gdƒžgdņegdŽZ˜„Š`„ŠgdY}ą„Š^„ŠgdY}ąŠ= > > >>f>g>h>i>l>s>v>{>|>}>ƒ>Š>>”>™>Ÿ> >”>ė>ń> ??3?]?c?v?w?x?Ž?? @¹@Ų@AAHAIA„AčAüųóīęįŁųÕųÕųŃųÕųÕųÕųĶČĄøĄøĄøĄø³¦¢ž–’Ž’†~vr~hĆŸhĆŸhS Ą5hĆŸhĆŸ5hĆŸh.} 5hČ.RhS ĄhS ĄhS Ą5hż7æh ;hż7æhd'€5B*ph’ hż7æ5hż7æh ;5hż7æhd'€5 hLĄ5hd'€h{]²hųa¬hÜh(.ē5 hõ^U5hÜhÜ5 hņe5 h{]²5hÜhƒž+}>Š>”>Ÿ> >”>x?y?}??…?‰?Ž?? @@?@u@«@Ł@AAIAJA[ArAśńśśśśśéééééäßß×××××ßßßßß & FgdS ĄgdS Ągdż7æ & Fgd ;„Š`„Šgdųa¬gdųa¬rAA‹AœA¤A„AźAėAļAóA÷AūABB“B”B«BĘBźBžBCCCC}D~DśśśśśśśņņņņéäääÜÜÜÜÜ×××××gdI & Fgdæfgdå „„Š^„Šgdæf & FgdĆŸgdS ĄčAéAźAūABBBwB‹BB‘B’B“BžBCCCCC{D|D}D‡EˆEŠE‹EEŽEE‘EčEéEļEšEńEśķéåįŁŃĢÄŃæ²å®åŖ„•ƒwswswswsiciXhq 0JmHnHu hō ©0Jjhō ©0JUhō ©jhō ©Uh^:hĻZéhI5B*ph’ hĻZé5hĻZéh^:5hĻZéhI5 hLĄ5hIh‘NĒhz·hå „5B*ph’ hz·5h‘NĒhC|ˆ5 hC|ˆ5h‘NĒhæf5h‘NĒhå „5hå „hæfhĆŸhå „hĆŸ5B*ph’ hå „5"~D°DįDE3E‡E‰EŠEŒEEEE’E“EµE¶EóEōEõEöE÷÷÷÷÷õõõõõõõõóóóõõ÷ & F gd^:ńEņEōEõEöEõńķéh^:hōSāhō ©jhō ©0JU,1h°Š/ °ą=!°"°# $ %°°Š°Š Š†œ@@ń’@ NormalCJ_HaJmH sH tH DA@ņ’”D Default Paragraph FontRió’³R  Table Normalö4Ö l4Öaö (kō’Į(No List4@ņ4 LĄHeader  ĘąĄ!4 @4 LĄFooter  ĘąĄ!.)@¢. LĄ Page Number<”’’’’  ’’ z™ ’’ z™ ’’ z™ ’’ z™ ’’ z™ ’’ z™ ’’ z™ ’’ z™ ’’  z™ ’’  z™ ’’  z™ ’’  z™ ’’  z™Š3R ¼9Œ*c$f)ę.°4%9<  ×   !"#$%‹ŒEu¤×Ų¤„¾Üś./01žĢē&Mƒ„…ŁŚēū  14ƒ›œÄį(HIÆ°Üų6YZ‰‹a b   ” ā ć m o Ģ Ķ \ ] ģ ķ R S T U › œ   ` a Ć Ä bcefŗ»ałgüHI²³Lzø¹ŗ½¾æ&9J`rst¾æĶÖäņ !+7DO[\ĘĒćž 3456789:;<=>?@Aāć1”ļq¾ŅÓŌRS‚›­ÖķīļHJT`owƒ„Žģīś 0123”¢£ņ4†×"#$%Š‹½ń:s±²³čéō&'()*+,Ŗ«  P Q { | ¦ § N!O!P!Q!R!S!™!š!ė!Ø"7#£#ā#ć#ä#å#ę# $!$,$7$F$S$a$b$c$d$e$¬$­$ŗ$Č$Õ$Ž$ļ$š$!%"%#%é&ź&''1'I'b'c'd'\(](q(ˆ( (¹(Ņ(Ó(Ō($)%)2)?)L)Z)f)h)i)j)k)ä)ę)ī)÷)’) ****ų*ł*+++'+5+6+7+»,¼,0-Ŗ-.f.ą.į.ā.ć.ä.å.ę.ē.č.X/Y/ę/Y0½01|1}1~1Ó1Ō12*2N2w2œ22Ż2Ž23j3•3Ü34444w4x4‚4Œ4™4£4®4Æ4°4‡5ˆ5Œ55”5˜55ž566N6„6ŗ6č677X7Y7j77Ž7š7«7³7“7ł7ś7ž788 888¢8£8ŗ8Õ8ł8 9#9$9%9&9Œ::æ:š:';B;¢;Ä;Å;<Ą!ėtĄ!ėtĄ!ėtĄ!ėtĄ!ėtĄ!ėtĄ!ėtĄ!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!ēĄ!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬Ą!¬ !"#$%‰‹ŒEu¤×Ų¤„¾Üś./01žĢē&Mƒ„…ŁŚēū  124ƒ›œÄį(HIÆ°Üų6YZ‰‹a b   ” ā ć m o Ģ Ķ \ ] ģ ķ R S T U › œ   ` a Ć Ä bcefŗ»ałgüHI²³Lzø¹ŗ»½¾æ&9J`rst¾æĶÖäņ !+7DO[\ĘĒćž 3456789:;<=>?@Aāć1”ļq¾ŅÓŌRS‚›­ÖķīļHJT`owƒ„‹Žģīś 0123”¢£ņ4†×"#$%Š‹½ń:s±²³čéō&'()*+,Ŗ«  P Q { | ¦ § N!O!P!Q!R!S!™!š!ė!Ø"7#£#ā#ć#ä#å#ę# $!$,$7$F$S$a$b$c$d$e$¬$­$ŗ$Č$Õ$Ž$ļ$š$!%"%#%é&ź&''1'I'b'c'd'\(](q(ˆ( (¹(Ņ(Ó(Ō($)%)2)?)L)Z)f)h)i)j)k)ä)ę)ī)÷)’) ****ų*ł*+++'+5+6+7+»,¼,0-Ŗ-.f.ą.į.ā.ć.ä.å.ę.ē.č.X/Y/ę/Y0½01|1}1~1Ó1Ō12*2N2w2œ22Ż2Ž23j3•3Ü34444w4x4‚4Œ4™4£4®4Æ4°4‡5ˆ5Œ55”5˜55ž566N6„6ŗ6č677X7Y7j77Ž7š7«7³7“7ł7ś7ž788 888¢8£8ŗ8Õ8ł8 9#9$9%9&9Œ::æ:š:';B;–;˜;™;›;œ;ž;Ÿ;”;¢;Ä;Å;<<<˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜! 0€€˜! 0€€˜! 0€€˜! 0€€˜! 0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜@0€€˜@0€€˜@0€€˜@0€€˜@0€€˜@0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€˜0€€˜0€€˜0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€˜0€€˜0€€˜0€€˜0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€˜ 0€€Iˆ00WIˆ00WIˆ00WIˆ00WIˆ00WIˆ00WIˆ00WIˆ00W˜0€€˜0€€˜0€€Iˆ00Wˆ0 ¢‹ŒEu¤×Ų1žĢē&Mƒ„…ŁŚēū  124›œÄį(HIYZa b   ” ā ć m o Ģ Ķ \ ] ģ ķ R S › œ   ` a Ć Ä bcef»ałgüHI³Lzø¹&9J`rstæĶÖäņ !7DO\Ēćž 3ŌS‚›­ÖķīļHT`owƒ„Žģīś 01”¢£ņ4†×"#$%Š‹½ń:s±³čéō&'()*Ŗ«  P Q { | N!O!P!™!š!ė!Ø"7#£#ā#ć#ä#å#ę# $!$,$7$F$S$a$b$c$d$e$­$ŗ$Č$Õ$Ž$ļ$é&ź&''1'I'c'd'\(](q(ˆ( (¹(Ņ($)%)?)L)Z)h)i)j)ä)ę)ī)÷)’)**ų*ł*+++'+5+6+7+»,¼,0-Ŗ-.f.į.X/Y/ę/½01|1}1Ó1Ō12*2N2w2œ22Ż2Ž23j3•3Ü3444w4x4‚4Œ4™4£4®4Æ4‡5ˆ5Œ55”5˜55ž566N6„6ŗ6č677X7Y7j77Ž7š7«7³7“7ł7ś7ž788 888<š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š0€€š 0€€š 0€€š 0€€š 0€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š 0€€€š 0€€€š 0€€€š 0€€€š 0€€€š0€€€š0€€€š0€€€š 0€€€š 0€€€š 0€€€š 0€€€š 0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š0€€€š 0€€€š 0€€€š 0€€€š 0€€š@0€€š@0€€š€€ mmmmmpó ¤ū„SÖ y""%)_+R.W/Ę2Ų3Š8Š=čAńEöE#&)+-/03468:;=>@BDGIŲ ē ‰æ\ļ‹"d(A+¹.#3­6Å;}>rA~DöE$'(*,.12579<?ACEFHõE%ahjp!’•€ˆ±ŗÕąåšõLSī÷%-!.O T E I Ū ę   ƒ Ž ē ī •œnz¢©żāä&+ū%*8=IN_ĄĮĆŹĖĶĪÖ×ćåņKS$2)/ŚäuMSX_ļšņłūüž  $/§ÆöŠ”Ūå²¼ĮĖęš.9hrw„°ŲåķóųŒ!–!ž!Ø!ļ!ł!Ó"Ż"A#J#q#€#Œ#™#š#¢#Ö#ą#$$0$6$;$E$®$Æ$±$¹$»$¼$¾$Č$É$Ź$Ģ$Õ$ā$ī$D%G%ū%&ė&ģ&ī&ō&õ&''''''''1'2'3'5'H'M'S'Ą'É'ä'ė'~(‡(ę)ē)é)ļ)ń)ų)ś)ž)’)*** ****++w+ƒ+ā,ļ,µ-Å-....Ņ4Ł4O5V5B6M6l6w6x6ƒ6¢6­6®6¹6Ü6ē67777£8Ŗ8Ā9É9’:™:Ö:Ż:-;8;>;A;–;<}ˆĄĢĪÕ×ćåńÖą¾ĒŲŚļłūƒˆŲę!–!®$¹$»$Ē$É$Ō$ė&''''0'2'H'h'k'))ę)ķ)ī)ö)÷)ž)’)* ****§.°.Q/V/Ģ1Ń12 2b2m2“4¶4¢5§5‰99–;<:::::::::::::::::::%!4p‘J'd'ŗ(Ō(x4°4ˆ5ž5ś78£8&9]::';B;–;¢;Ć;Å;÷;<<!ń[q<Ļ>’’’’’’’’’s3ägœb’’’’’’’’’=ž4N€x’’’’’’’’’Ÿ+—–ąLn’’’’’’’’’7)Š ”iśĻ’’’’’’’’’| ū z-Ō„’’’’’’’’’’.1P¦ģ’’’’’’’’’5ķ™¢‘’’’’’’’’’?ź˜’¬Č’’’’’’’’’"ėžõŹ@’’’’’’’’’nb$"Ī’’’’’’’’’…ņ$®*žØ’’’’’’’’’/V0Šun>’’’’’’’’’A"­0źŗ®’’’’’’’’’— Ģ2Ž0“ę’’’’’’’’’†e™5VšŌ;’’’’’’’’’5/ 6\!_’’’’’’’’’}|1;Ōü1’’’’’’’’’0~B¢¹b}’’’’’’’’’ŽI{LŲSŽ’’’’’’’’’ˆcÓM&DtC’’’’’’’’’ĢI0U§¶Ŗ’’’’’’’’’]xÜŽ’’’’’’’’’-b Z’’’’’’’’’SjTc° Zź’’’’’’’’’[o0g”8l’’’’’’’’’#g&N”’’’’’’’’’Yrźć¦3’’’’’’’’’ZXu“Ėī™’’’’’’’’’PjĆv™D‰’’’’’’’’’Ä0Šwf@I’’’’’’’’’¬2ܤTłø&®ŌŌśŠŃ5pÜ.Žlėj#in$,1/‘0VM1‰N2ģ 4ß<4āI4‹@5^:;č*;ÄH<Ī$>KV?QOAgA¢QFoFŚG„LG>mH”BN-PČ.RßdSņ7Tõ^USVSWYWfY$D[[ ]+O^žK_6`nbēcņpcpVdņe»'gźaj²*koy?rėTrSds(0w{4w®pxpQyžzyu?{”.|ü'}Ļnd'€S€‹<ūƒ„s„zW†%‡C|ˆī+Œ(tßŽ!G ;P1’ąQ“M”z)˜ŽZ˜Õ™{[›¤RœƒžZžĆŸ“eŸÄ_”6K¢(¤å „yo„ō ©sD© |Ŗ>¬ųa¬±&®tB®; °{]²ģ³‡G¶z·äøŌyøL¹©=¼ed¼’/½†M½P½“z¾ż7æS Ą#GĄLĄcĀz*ÅmhĘßwʑNĒ¤ČyČ1=ĢŻ:Ķ¢7Ī$Ļ>ĻŃŅKŃŁ[Óų/ŌķÕ»aÕ@×5ŲģŚĘKŪBÜĮlŻ«ąY}ąōSā; äQEę(.ēm\čĻZé}dķ5"īLšEXńą`õdeö(Iś@güüž’@€Ų,O(<@@@$@L@’’Unknown’’’’’’’’’’’’G‡z €’Times New Roman5€Symbol3& ‡z €’Arial;€Wingdings?5 ‡z €’Courier New7& ‡ ŸVerdana"qˆšŠhœ:¶†ęBĀ¦ä²2 lä²2 l!š ““24x;x;!3ƒQšHX š’?ä’’’’’’’’’’’’’’’’’’’’’@gü2’’ Nutrition MCQMelanie StapletonFaculty of Medicine!                           ž’ą…ŸņłOh«‘+'³Ł0˜°¼Ųäš , L X dpx€ˆäNutrition MCQMelanie Stapleton Normal.dotFaculty of Medicine4Microsoft Office Word@Œ†G@Pń1)©Ē@ōōŗjČ ä²2ž’ÕĶ՜.“—+,ł®0ō hp|„Œ” œ¤¬“ ¼ Öä lx;Ä Nutrition MCQ Title  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJž’’’LMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€‚ƒ„…†‡ˆ‰Š‹ŒŽ‘’“”•–—˜™š›œžŸ ”¢£¤„¦§Ø©Ŗ«¬­®Æ°±²³“µ¶·ø¹ŗ»¼½¾æĄĮĀĆž’’’ÅĘĒČÉŹĖž’’’ĶĪĻŠŃŅÓž’’’ż’’’ż’’’מ’’’ž’’’ž’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’Root Entry’’’’’’’’ ĄF@÷oŹjČŁ€1Table’’’’’’’’KXńWordDocument’’’’’’’’.”SummaryInformation(’’’’ÄDocumentSummaryInformation8’’’’’’’’’’’’ĢCompObj’’’’’’’’’’’’q’’’’’’’’’’’’’’’’’’’’’’’’ž’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ž’ ’’’’ ĄFMicrosoft Office Word Document MSWordDocWord.Document.8ō9²q